🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. IMMUNE RESET TO ALLOW ACCESS TO HLA-COMPATIBLE KIDNEY TRANSPLANTATION IN HYPERIMMUNIZED PATIENTS

    The George Institute

    chronic kidney disease, Hypersensitized patients

    phase 2 other active

    1 trial

  2. INAVOLISIB, FULVESTRANT, INAVOLISIB

    Hoffmann-La Roche

    Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA)-Mutated, hormone receptor-positive (HR-Positive), human epidermal growth factor receptor 2 (HER2)-Negative Locally Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  3. INDOCYANINE GREEN

    The George Institute

    Patients with primary invasive early breast cancer (T1-T2) that will undergo planned breast-conserving surgery

    phase 2 small molecule active

    1 trial

  4. INZ-701

    Lacuna Pharma Pty Ltd

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency and ATP-binding cassette sub-family C member 6 (ABCC6) Deficiency, Generalized Arterial Calcification of Infancy (GACI), Pseudoxanthoma elasticum (PXE)

    phase 2 small molecule active

    1 trial

  5. ION582

    IONIS PHARMACEUTICALS INC

    Angelman syndrome

    phase 2 small molecule active

    1 trial

  6. IONIS-FB-LRx

    IONIS PHARMACEUTICALS INC

    Macular Degeneration

    phase 2 small molecule completed

    1 trial

  7. IONIS-FB-Lrx

    IONIS PHARMACEUTICALS INC

    Geographic Atrophy

    phase 2 small molecule terminated

    1 trial

  8. IPTACOPAN, Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023)

    Novartis Pharmaceuticals

    active antineutrophilic cytoplasmic antibody (ANCA) associated vasculitis

    phase 2 small molecule active

    1 trial

  9. IRINOTECAN, CALCIUM LEVOFOLINATE, ivonescimab, FOLINIC ACID, OXALIPLATIN, PACLITAXEL, FLUOROURACIL

    Ningbo Cancer Hospital

    Metastatic or locally advanced irresectable (stage IV) gastric cancer (GC) or esophagogastric junction cancer (EGJC), with and without actionable biomarker (HER2/Claudin18.2)

    phase 2 small molecule active

    1 trial

  10. IRINOTECAN, FOLINIC ACID, FLUOROURACIL, DOMVANALIMAB, FLUOROURACIL, ZIMBERELIMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    stomach cancer, Esophage, gastro-oesophageal junction adenocarcinoma

    phase 2 small molecule active

    1 trial

  11. ISA101b

    Regeneron UK Limited

    Squamous Cell Carcinoma of the Oropharynx

    phase 2 mab active

    2 trials

  12. ISIS 416858

    IONIS PHARMACEUTICALS INC

    End-stage Renal Disease (ESRD)

    phase 2 small molecule completed

    2 trials

  13. IVERMECTIN

    The George Institute

    Strongyloidiasis is caused by a parasite that is globally distributed in tropical and sub-tropical areas. Most patients with strongyloidiasis are asymptomatic or have mild symptoms with gastrointestinal disturbances, respiratory symptoms, and skin lesions. In situations of low defenses (patients under treatment with corticosteroids, organ transplant recipients or other situations) they can present serious complications with high mortality.

    phase 2 small molecule active

    1 trial

  14. IW-3718

    IRONWOOD PHARMACEUTICALS INC

    Gastroesophageal Reflux

    phase 2 small molecule completed

    1 trial

  15. IW-3718

    IRONWOOD PHARMACEUTICALS INC

    Gastroesophageal Reflux Disease

    phase 2 small molecule completed

    1 trial

  16. Iberdomide, Iberdomide, Iberdomide, Iberdomide, Dexamethasone Tablets BP 2.0mg, Iberdomide, Iberdomide, Iberdomide, Dexamethasone 2mg Tablets , Iberdomide, Iberdomide, DARZALEX 1800 mg solution for injection, Iberdomide, Iberdomide, Iberdomide, Dexamethason-ratiopharm® 4 mg Tabletten

    Celgene Europe Limited

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  17. Iclusig 15 mg film-coated tablets

    Ningbo Cancer Hospital

    Chronic myelogenous leukemia

    phase 2 small molecule active

    1 trial

  18. Icotinib

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  19. Ifinatamab Deruxtecan

    Merck Sharp and Dohme

    Esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  20. Ifinatamab deruxtecan

    Daiichi Sankyo

    Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma)

    phase 2 small molecule active

    1 trial

  21. Ifinatamab deruxtecan

    Daiichi Sankyo

    Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  22. Ilofotase alfa, Ilofotase alfa Placebo Drug Product

    Lacuna Pharma Pty Ltd

    Risk for renal damage following open heart surgery

    phase 2 small molecule active

    1 trial

  23. Immunological Agent

    The First People's Hospital of Lianyungang

    Lung Cancer Metastatic

    phase 2 small molecule active

    1 trial

  24. Immunomodulatory DC vaccines to target prostate cancer

    Shenzhen Second People's Hospital

    Prostate Cancer Indications

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources